AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Company Profile for Immune-Onc Therapeutics, Inc.

November 21, 2019 GMT

--(BUSINESS WIRE)--Nov 21, 2019--

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com.

Company:

Immune-Onc Therapeutics, Inc.

 

 

Headquarters Address:

795 San Antonio Road

 

Palo Alto, CA 94303

 

 

Main Telephone:

16504571745

 

 

Website:

www.Immune-Onc.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Charlene Liao

 

 

Public Relations

 

Contact:

Tara Cooper

Phone:

650-303-7306

Email:

media@immuneonc.com

 

View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005345/en/

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Immune-Onc Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/21/2019 03:55 AM/DISC: 11/21/2019 03:55 AM

http://www.businesswire.com/news/home/20191121005345/en